Mr. Robert Andrade reports

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

The nominees listed in Fennec Pharmaceuticals Inc.'s management proxy circular dated April 25, 2025, were elected as directors of the company at the annual general and special meeting of shareholders held in New York, N.Y., on June 3, 2025.

Detailed results of the vote for the election of directors are set out in the attached table.

Shareholders voted 99.64 per cent in favour of appointing Haskell & White LLP as auditor and authorizing the directors to fix the auditor remuneration, 85.50 per cent in favour of the compensation paid to the company's named executive officers, and 91.27 per cent (88.01 per cent after subtracting shares held by insiders eligible to participate in the company's 2020 equity incentive plan) in favour of certain amendment to the company's 2020 equity incentive plan.

The company has relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the Toronto Stock Exchange will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, in the approval of the amendments to its 2020 equity incentive plan.